首页
登录
职称英语
Small, pink and very ugly. Hardly the qualities of a star, but they describe
Small, pink and very ugly. Hardly the qualities of a star, but they describe
游客
2025-05-08
43
管理
问题
Small, pink and very ugly. Hardly the qualities of a star, but they describe the deformed mouse that was the media darling at a recent science exhibition in Beijing. With a complex tissue structure in the shape of a human ear grafted on to its back, the rosy rodent was a stunning symbol of the serious strides China is making in the field of biotechnology.
China is fast applying the latest life-science techniques learned from the West m aggressively pursue genome research. It’s establishing its own centers of technical excellence to build a scientific base to compete directly with the United States and Europe. With a plentiful supply of smart young scientists at home and lots of interest abroad biotechnology is on the brink of a boom in China and in the view of foreign scientists, Beijing is playing a clever hand, maximizing the opportunities open to them.
For the moment, the cooperation exists mostly with Europe and the U. S. But Asia’s other biotech leaders, Japan, Singapore and Korea, also are recognizing China’s potential as an attractive low-cost base to conduct research. These partnerships--and China’s advancement in the field of biotechnology--could help benefit the rest of Asia: China’s rapid progress in improving crop yields will address food-security concerns in the region. In addition, China is more likely to focus on developing cheap technology that its predominantly poor population--and those of other Asian countries--can afford.
There remain, however, serious barriers to the development of a strong biotech industry. Among them are a poor domestic legal framework, weak enforcement of intellectual-property rights and loose adherence to international standards. China is a signatory of the International Bio Safety Protocol, which should mean adherence to global standards governing the conduct of field trims. But some observers are skeptical. "The regulations look good, but I haven’t met one scientist who believes they are being fully adhered to," says a European science analyst.
If shortcuts are taken, then some of the recent scientific achievements trumpeted in the official press may never make it to market. But no matter how strict lab tests are, other problems lie in wait. For example, there is a number of tasks it would take years to fulfill in the patents office, says one lawyer, leaving innovators with little protection if they take a product to market in China. [br] Science analysts are worried that China, in the course of biotech development, ______.
选项
A、might refuse to join efforts to adhere to global standards
B、may put too much emphasis on developing cheap technology
C、cannot afford to fulfill years of tasks in assessing patents
D、may not seriously follow the International Bio Safety Protocol
答案
D
解析
转载请注明原文地址:https://tihaiku.com/zcyy/4067309.html
相关试题推荐
Small,pinkandveryugly.Hardlythequalitiesofastar,buttheydescribe
Small,pinkandveryugly.Hardlythequalitiesofastar,buttheydescribe
Hardly______whenaloudexplosionwasheard.A、thetrainhadstartedB、thetrai
Tomcouldhardly______hisexcitementasheknewthathehadmadearealdiscov
Anoldwomanwasbadlyhurtin______thepolicedescribeasanapparentlymotiv
Icanhardlyreadyourwriting.Itis______.A、illegibleB、illegalC、eligibleD、
Hardlyanything______morethanhappinessofseeingsomeoneusinghisdevicefor
Theword"foolish"istoomildtodescribeyourbehavior,Iwouldpreferthewor
Therewas(hardlysomebody)intheroomwhopaid(any)attentiontohim(eventh
Theword"foolish"istoomildtodescribeyourbehavior,Iwouldpreferthewor
随机试题
In1993,NewYorkStateorderedstorestochargeadepositonbeverage(饮料)
A.0.5kN,向左 B.1kN,向左 C.2kN,向左 D.3kN,向左
软件的质量需求是软件需求的一部分,根据《软件工程产品质量第1部分:质量模型
弦脉与紧脉的脉象区别点是A.脉位深浅不同 B.脉搏弹性高低不同 C.脉搏流利
不属于炎性细胞的是( )。A.中性粒细胞 B.淋巴细胞 C.红细胞 D.
关于人体内正常菌群的叙述,错误的是A.菌群失调可导致感染 B.正常菌群大部分是
对尊重患者自主权的正确理解是A.必须听从有地位的患者的决定 B.此准则适用于所
甲企业的产品组合为3种洗衣粉、4种香皂、5种纸巾和6种洗发水,共18种产品。目前
关于建筑项目能耗水平分析评价的说法,正确的有()。(新教材已删除)A.公共
在体内可由胆固醇转变成的维生素是A:维生素A B:泛酸 C:维生素E D:
最新回复
(
0
)